{"id":153200,"date":"2022-12-19T13:22:41","date_gmt":"2022-12-19T19:22:41","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/12\/fda-approves-gene-therapy-for-tough-to-treat-bladder-cancer"},"modified":"2022-12-19T13:22:41","modified_gmt":"2022-12-19T19:22:41","slug":"fda-approves-gene-therapy-for-tough-to-treat-bladder-cancer","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/12\/fda-approves-gene-therapy-for-tough-to-treat-bladder-cancer","title":{"rendered":"FDA Approves Gene Therapy for Tough-to-Treat Bladder Cancer"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/fda-approves-gene-therapy-for-tough-to-treat-bladder-cancer.jpg\"><\/a><\/p>\n<p>MONDAY, Dec. 19, 2022 (HealthDay News) \u2014 Patients with a high-risk bladder cancer now have a new option to treat it.<\/p>\n<p>The U.S. Food and Drug Administration on Friday approved a gene therapy called Adstiladrin, which is designed to work for patients who have what\u2019s called high-risk non-muscle-invasive bladder cancer (NMIBC) that hasn\u2019t responded to the standard treatment, Bacillus Calmette-Gu\u00e9rin (BCG), but hasn\u2019t spread. BCG is a vaccine typically used for tuberculosis.<\/p>\n<p>\u201cThis approval provides health care professionals with an innovative treatment option for patients with high-risk NMIBC that is unresponsive to BCG therapy,\u201d <a href=\"https:\/\/www.fda.gov\/about-fda\/fda-organization\/peter-marks\">Dr. Peter Marks<\/a>, director of the FDA\u2019s Center for Biologics Evaluation and Research, said in an agency <a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treatment-high-risk-non-muscle-invasive-bladder-cancer\">news release<\/a>. \u201cToday\u2019s action addresses an area of critical need. The FDA remains committed to facilitating the development and approval of safe and effective cancer treatments.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MONDAY, Dec. 19, 2022 (HealthDay News) \u2014 Patients with a high-risk bladder cancer now have a new option to treat it. The U.S. Food and Drug Administration on Friday approved a gene therapy called Adstiladrin, which is designed to work for patients who have what\u2019s called high-risk non-muscle-invasive bladder cancer (NMIBC) that hasn\u2019t responded to [\u2026]<\/p>\n","protected":false},"author":511,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1495],"tags":[],"class_list":["post-153200","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-health"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/153200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/511"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=153200"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/153200\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=153200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=153200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=153200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}